MedKoo Cat#: 564653 | Name: VU0134992
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VU0134992 is a selective blocker of the inward-rectifier potassium channel Kir4.1, exhibiting an IC₅₀ of 0.97 μM. It demonstrates approximately 10-fold selectivity over Kir4.1/5.1 concatemeric channels and over 30-fold selectivity compared to Kir1.1, Kir2.1, and Kir2.2 channels. In vivo studies have shown that oral administration of VU0134992 in rats leads to dose-dependent increases in urine output and excretion of sodium and potassium ions, highlighting its potential as a tool for exploring Kir4.1's role in renal function.

Chemical Structure

VU0134992
VU0134992
CAS#755002-90-5

Theoretical Analysis

MedKoo Cat#: 564653

Name: VU0134992

CAS#: 755002-90-5

Chemical Formula: C20H31BrN2O2

Exact Mass: 410.1569

Molecular Weight: 411.38

Elemental Analysis: C, 58.39; H, 7.60; Br, 19.42; N, 6.81; O, 7.78

Price and Availability

Size Price Availability Quantity
10mg USD 500.00
50mg USD 1,250.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
VU-992; VU 992; VU992; VU-0134992; VU 0134992; VU0134992
IUPAC/Chemical Name
2-(2-Bromo-4-isopropylphenoxy)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide
InChi Key
OTTDLWFVHQYRDA-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H31BrN2O2/c1-13(2)14-7-8-17(16(21)9-14)25-12-18(24)22-15-10-19(3,4)23-20(5,6)11-15/h7-9,13,15,23H,10-12H2,1-6H3,(H,22,24)
SMILES Code
O=C(NC1CC(C)(C)NC(C)(C)C1)COC2=CC=C(C(C)C)C=C2Br
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 411.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jiang YH, Li T, Liu Y, Liu X, Jia S, Hou C, Chen G, Wang H, Ling S, Gao Q, Wang XR, Wang YF. Contribution of inwardly rectifying K+ channel 4.1 of supraoptic astrocytes to the regulation of vasopressin neuronal activity by hypotonicity. Glia. 2023 Mar;71(3):704-719. doi: 10.1002/glia.24306. Epub 2022 Nov 21. PMID: 36408843. 2: Lu J, Azad MAK, Moreau JLM, Zhu Y, Jiang X, Tonta M, Lam R, Wickremasinghe H, Zhao J, Wang J, Coleman HA, Formosa LE, Velkov T, Parkington HC, Combes AN, Rosenbluh J, Li J. Inwardly rectifying potassium channels mediate polymyxin- induced nephrotoxicity. Cell Mol Life Sci. 2022 May 15;79(6):296. doi: 10.1007/s00018-022-04316-z. PMID: 35570209; PMCID: PMC9108107. 3: Isaeva E, Bohovyk R, Fedoriuk M, Shalygin A, Klemens CA, Zietara A, Levchenko V, Denton JS, Staruschenko A, Palygin O. Crosstalk between epithelial sodium channels (ENaC) and basolateral potassium channels (Kir 4.1/Kir 5.1) in the cortical collecting duct. Br J Pharmacol. 2022 Jun;179(12):2953-2968. doi: 10.1111/bph.15779. Epub 2022 Feb 7. PMID: 34904226; PMCID: PMC9106811. 4: Weaver CD, Denton JS. Next-generation inward rectifier potassium channel modulators: discovery and molecular pharmacology. Am J Physiol Cell Physiol. 2021 Jun 1;320(6):C1125-C1140. doi: 10.1152/ajpcell.00548.2020. Epub 2021 Apr 7. PMID: 33826405; PMCID: PMC8285633. 5: Kharade SV, Kurata H, Bender AM, Blobaum AL, Figueroa EE, Duran A, Kramer M, Days E, Vinson P, Flores D, Satlin LM, Meiler J, Weaver CD, Lindsley CW, Hopkins CR, Denton JS. Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Mol Pharmacol. 2018 Aug;94(2):926-937. doi: 10.1124/mol.118.112359. Epub 2018 Jun 12. PMID: 29895592; PMCID: PMC6041953.